Not every patient will be well suited for GLP 1 therapy
#Neuropharmacology #ClinicalPharmacology #CNSDrugs #DrugInteractions #Pharmacokinetics #Pharmacodynamics #Neuroscience To view or add a comment, sign in Non-animal models (NAMs) are critical tools for drug development
Additionally, it plays a role in signaling pathways that promote cellular repair and regeneration
Led by Amina Haggag, MD, FAAFP, CDE, CPI, Anna Parker, DCN, RDN, CDCES and Yulia Naumova our team shared clinical recommendations for managing adverse events in patients treated with GLP-1 receptor agonists, including strategies for: Nausea Vomiting Diarrhea Constipation We also highlighted our approaches to compliance and retention in long-term studies, focusing on: Study Participant Motivation Flexible Scheduling Accessible Communications Building Relationships Our dedication to patient care and the success of our studies distinguishes us
Please inform your Flow Wellness clinician regarding any reactions